Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
Antoine Angelergues
Honoraria - Sanofi
Denis Maillet
No relevant relationships to disclose
Aude Flechon
Honoraria - Astellas Pharma; Ferring; Janssen; Sanofi
Mustafa Ozguroglu
Consultant or Advisory Role - Astellas Pharma; Janssen; Sanofi
Florence Mercier
Consultant or Advisory Role - Boston Scientific; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Sanofi
Aline Guillot
No relevant relationships to disclose
Sylvestre Le Moulec
No relevant relationships to disclose
Gwenaelle Gravis
Consultant or Advisory Role - Sanofi (U)
Philippe Beuzeboc
Consultant or Advisory Role - Astellas Pharma; Ipsen; Janssen; Sanofi
Honoraria - Astellas Pharma; Ipsen; Janssen; Sanofi
Christophe Massard
Consultant or Advisory Role - Janssen; Sanofi
Honoraria - Janssen; Sanofi
Thibault De La Motte Rouge
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Astellas Pharma
Nicolas Delanoy
No relevant relationships to disclose
Reza-Thierry Elaidi
No relevant relationships to disclose
Stephane Oudard
Consultant or Advisory Role - Amgen; Bayer; Keocyt; Novartis; Roche; Sanofi
Honoraria - Amgen; Bayer; Keocyt; Novartis; Pfizer; Roche; Sanofi